The Pharmaletter

One To Watch

enchance3d-genomis-large-1

Enhanc3D Genomics

A company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery.

Enhanc3D Genomics has established a genome-wide 3D-sequencing platform (GenLink3D) that can globally connect enhancer regions and GWAS (genome-wide association study) risk loci to their core target genes. The GenLink3D platform pipeline is an elegant combination of a proprietary molecular assay with advanced algorithms and machine-learning capability, providing the first genome-wide, high-resolution, mapping of DNA interactions in 3D space.

The company is using this technology to mine the untapped resource of non-coding genome interactions to create an extensive database of candidate therapeutic targets for development with pharmaceutical partners.

Want to Update your Company's Profile?


Latest Enhanc3D Genomics News

More Enhanc3D Genomics news >